# US 10,872,696 B2 · Method of hypoglycemia risk determination > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,872,696 B2 - Document ID: US10872696B2 - Status: Granted - Kind: B2 - Application number: 15/427,586 - Filed: 2017-02-08 - Published: 2017-05-25 - Granted: 2020-12-22 - Earliest claimed: 2011-02-11 - Assignees: Abbott Diabetes Care Inc. - Applicants: Abbott Diabetes Care Inc. - Inventors: Daniel M. Bernstein; Kenneth J. Doniger; Timothy C. Dunn; Gary A. Hayter; Howard Wolpert - Web page: https://patentgrep.com/patent/US10872696B2 ## CPC - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - A61B 5/0022: {Monitoring a patient using a global network, e.g. telephone networks, internet} - A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement} - A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes} - A61B 5/150358: {Strips for collecting blood, e.g. absorbent} - A61B 5/151: {Devices} specially adapted for taking samples of capillary blood, e.g. by lancets {, needles or blades} - A61B 5/4839: {combined with drug delivery} - A61B 5/486: {Biofeedback (using electroencephalography [EEG] A61B5/375)} - A61B 5/6898: {Portable consumer electronic devices, e.g. music players, telephones, tablet computers} - A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor} - A61B 5/742: {using visual displays (displays for heart-related electrical signals, e.g. ECG, A61B5/339)} - A61B 5/743: {Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots} - A61B 5/7475: {User input or interface means, e.g. keyboard, pointing device, joystick} - G16H 10/20: for electronic clinical trials or questionnaires - G16H 20/17: delivered via infusion or injection - G16H 40/63: for local operation - G16H 40/67: for remote operation - G16H 50/30: for calculating health indices; for individual health risk assessment - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) ## Abstract Presented herein are one or more software applications to help a user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with an analyte measurement device. ## Claims ### Claim 1 A computer-implemented method for hypoglycemia risk determination and treatment recommendation, the method comprising: collecting, by one or more computing devices, a plurality of analyte concentration measurements generated by an in vivo analyte monitoring system, the in vivo analyte monitoring system comprising at least a portion of an analyte sensor in contact with a bodily fluid of a user; executing, by one or more processors of the one or more computing devices, software configured to perform the following steps: (a) determining a first median value for the plurality of analyte concentration measurements corresponding to a first time of day period; (b) determining a first variability value for the plurality of analyte concentration measurements corresponding to the first time of day period; (c) determining, with reference to a data space defined by a range of median analyte concentration values and a range of variability analyte concentration values where the data space comprises a plurality of zones, if a first zone of the plurality of zones includes the first median value and the first variability value, wherein the first zone is associated with a risk of hypoglycemia, and (d) if it is determined that the first median value and the first variability value are included in the first zone, then outputting either a representation of the first zone or a treatment recommendation based on the first zone, wherein the treatment recommendation is related to a medication adjustment or food intake. ### Claim 2 (depends on 1) The method of claim 1, wherein the first zone is defined by a hypoglycemia risk boundary, wherein the first zone comprises a plurality of median values that are less than the hypoglycemia risk boundary. ### Claim 3 (depends on 2) The method of claim 2, wherein the hypoglycemia risk boundary is either a straight hypoglycemia risk line or a curved hypoglycemia risk line. ### Claim 4 (depends on 1) The method of claim 1, wherein the representation of the identified first zone is output in (d), wherein the representation indicates hypoglycemia risk. ### Claim 5 (depends on 1) The method of claim 1, wherein the treatment recommendation is output in (d). ### Claim 6 (depends on 2) The method of claim 2, wherein the first variability value is a variability of the analyte concentration measurements in a range from the first median value to a tenth percentile value less than the median value, wherein when the plurality of analyte measurement concentrations are sorted from a highest to a lowest value, the tenth percentile value is the value in which about ninety percent of the analyte measurement concentrations are above the tenth percentile value and about ten percent of the analyte measurement concentrations are below the tenth percentile value. ### Claim 7 (depends on 2) The method of claim 2, wherein the first variability value is a variability of the analyte concentration measurements in a range from the first median value to an amount less than the first median value when the analyte concentration measurements are sorted from a highest to a lowest value. ### Claim 8 (depends on 2) The method of claim 2, further comprising adjusting, with the software executed by the one or more processors, the hypoglycemia risk boundary prior to determining if the first zone, from the plurality of zones, includes the first median value and the first variability value. ### Claim 9 (depends on 1) The method of claim 1, wherein the analyte concentration measurements comprise glucose data. ### Claim 10 (depends on 1) The method of claim 1, wherein the software, when executed by the one or more processors of the one or more computing devices, is further configured to perform the following steps: (e) determining a second median value for a plurality of analyte concentration measurements corresponding to a second time of day period and a second variability value for the plurality of analyte concentration measurements corresponding to the second time of day period; (f) determining with reference to the data space, if a second zone from the plurality of zones includes the second median value and the second variability value, wherein the second zone is associated with a risk of hypoglycemia, and (g) if it is determined that the second median value and the second variability value are included in the second zone, outputting a representation of the second zone. ### Claim 11 (depends on 10) The method of claim 10, further comprising: displaying a first treatment recommendation to the user based on the first zone for the first median value and the first variability value; and displaying a second treatment recommendation to the user based on the second zone for the second median value and the second variability value. ### Claim 12 A computer-implemented method for hypoglycemia risk determination and treatment recommendation, the method comprising: collecting, by one or more computing devices, a plurality of analyte concentration measurements generated by an in vivo analyte monitoring system, the in vivo analyte monitoring system comprising at least a portion of an analyte sensor that is in contact with a bodily fluid of a user; executing, by one or more processors of the one or more computing devices, software configured to perform the following steps: (a) determining a first central tendency value for the plurality of analyte concentration measurements corresponding to a first time of day period; (b) determining a first variability value for the plurality of analyte concentration measurements corresponding to the first time of day period; (c) determining, with reference to a data space defined by a range of central tendency values and a range of variability values where the data space comprises a plurality of zones, if a first zone of the plurality of zones includes the first central tendency value and the first variability value, wherein the first zone is associated with a risk of hypoglycemia, and (d) if it is determined that the first central tendency value and the first variability value are included in the first zone, outputting either a representation of the first zone or a treatment recommendation based on the first zone, wherein the treatment recommendation is related to a medication adjustment or food intake. ### Claim 13 (depends on 12) The method of claim 12, wherein the first zone is defined by a hypoglycemia risk boundary, wherein the first zone includes a plurality of central tendency values that are less than the hypoglycemia risk boundary. ### Claim 14 (depends on 12) The method of claim 12, wherein the representation indicates hypoglycemia risk. ### Claim 15 (depends on 13) The method of claim 13, further comprising displaying a treatment recommendation to the user based on the identified first zone. ### Claim 16 (depends on 13) The method of claim 13, wherein the first variability value is a variability of the analyte concentration values in a range from the first central tendency value to a tenth percentile value less than the first central tendency value, wherein when the plurality of analyte measurement concentrations are sorted from a highest to lowest central tendency value, the tenth percentile value is the value in which about ninety percent of the central tendency values are above the tenth percentile value and about ten percent of the central tendency values are below the tenth percentile value. ### Claim 17 (depends on 13) The method of claim 13, wherein the first variability value is a variability of the analyte concentration values in a range from the first central tendency value to an amount less than the first central tendency value when the central tendency values are sorted from a highest to a lowest value. ### Claim 18 (depends on 13) The method of claim 13, further comprising adjusting, with the software executed by the one or more processors, the hypoglycemia risk boundary prior to determining if the first one zone, from the plurality of zones, includes the first central tendency value and the first variability value. ### Claim 19 (depends on 12) The method of claim 12, wherein the analyte concentration measurements comprise glucose data. ### Claim 20 (depends on 12) The method of claim 12, wherein the software, when executed by the one or more processors of the one or more computing devices, is further configured to perform the following steps: (e) determining a second a central tendency value for the plurality of analyte concentration measurements corresponding to a second time of day period and a second variability value for the plurality of analyte concentration measurements corresponding to the second time of day period; (f) determining, with reference to the data space, if a second zone from the plurality of zones includes the second central tendency value and the second variability value, wherein the second zone is associated with a risk of hypoglycemia; and (g) outputting a representation of the identified second zone if it is determined that the second central tendency value and the second variability value are included in the second zone. ### Claim 21 (depends on 20) The method of claim 20, further comprising: displaying a first treatment recommendation to the user based on the first zone for the first central tendency value and the first variability value; and displaying a second treatment recommendation to the user based on the second zone for the second central tendency value and the first variability value. ### Claim 22 (depends on 1) The method of claim 1, wherein the one or more computing devices comprise one or more cloud-based servers. ### Claim 23 (depends on 1) The method of claim 1, wherein the one or more computing devices comprise a smart phone. ### Claim 24 (depends on 1) The method of claim 1, wherein the representation of the first zone is output in (d). ### Claim 25 A system for hypoglycemia risk determination and treatment recommendation, the system comprising: one or more in vivo analyte monitoring systems, each comprising at least a portion of an analyte sensor in contact with a bodily fluid of a user; one or more computing devices configured to collect a plurality of analyte concentration measurements generated by the one or more in vivo analyte monitoring systems, wherein the one or more computing devices comprises one or more processors and memory coupled thereto, the memory storing software that, when executed by the one or more processors, cause the one or more processors to perform the following steps: (a) determine a first median value for the plurality of analyte concentration measurements corresponding to a first time of day period; (b) determine a first variability value for the plurality of analyte concentration measurements corresponding to the first time of day period; (c) determine, with reference to a data space defined by a range of median analyte concentration values and a range of variability analyte concentration values where the data space comprises a plurality of zones, if a first zone of the plurality of zones includes the first median value and the first variability value, wherein the first zone is associated with a risk of hypoglycemia, and (d) if it is determined that the first median value and the first variability value are included in the first zone, then output a treatment recommendation based on the first zone, wherein the treatment recommendation is related to a medication adjustment or food intake. ### Claim 26 (depends on 25) The system of claim 25, wherein the analyte concentration measurements comprise glucose data. ### Claim 27 (depends on 25) The system of claim 25, wherein the first zone is defined by a hypoglycemia risk boundary, wherein the first zone comprises a plurality of median values that are less than the hypoglycemia risk boundary.